Embla Genomics ApS: Financial statements 2024
CVR: 41685603
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Embla Genomics ApS (CVR 41685603) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -8,262 and a net result of DKK -7,604 compared with DKK -10,591 the year before. Equity in the 2024 report amounted to DKK 42,277. The solvency ratio was 80.9%.
- Gross Profit
- DKK -8,262
- Profit/Loss
- DKK -7,604
- Equity
- DKK 42,277
- Total Assets
- DKK 52,277
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -8K | -8K | 42K | 0 |
| 2023 | - | -9K | -11K | 50K | 0 |
| 2022 | - | -10K | -8K | 60K | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Embla Genomics ApS has published its annual report for 2023. Gross profit came to DKK -9,205, and the net result was DKK -10,591.
About Embla Genomics ApS
Embla Genomics ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company has been dissolved on 19 October 2026. The company was registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company has 2 employees (2021). In 2025, the company reported a gross profit of DKK 14,722 and a net result of DKK 7,398 compared with DKK -7,604 the year before. Equity in the 2025 report amounted to DKK 49,675.